April 2019

Fact.MR has announced the addition of the “Cannabidiol Market Forecast, Trend Analysis Competition Tracking – Global Review 2017 to 2026″report to their offering. This press release was orginally distributed by SBWire Pune, Maharashtra — (SBWIRE) — 04/30/2019 — Cannabidiol Market Insights The cannabidiol marketplace is likely to witness significant RD investment in the pharmaceutical industry […]

by

Brokerages forecast that Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) will post earnings of ($0.46) per share for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Zynerba Pharmaceuticals’ earnings. Zynerba Pharmaceuticals reported earnings of ($0.91) per share during the same quarter last year, which suggests a positive year over year growth rate of 49.5%. […]

by

Shares of Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) were up 6.8% during trading on Monday . The stock traded as high as $11.81 and last traded at $11.74. Approximately 61,154 shares changed hands during mid-day trading, a decline of 98% from the average daily volume of 3,139,999 shares. The stock had previously closed at $10.99. Several analysts […]

by

Company on track to report top-line data in July/August time frame JERUSALEM, April 30, 2019 /PRNewswire/ — Intec Pharma Ltd. (NASDAQ: NTEC) (“Intec” or “the Company”) today announces that the last patient has completed their final visit in the Company’s pivotal Phase 3 trial (the ACCORDANCE trial) evaluating the safety and efficacy of the Accordion […]

by

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) announced Tuesday that the US Patent and Trademark Office has issued a new patent to the company for its transdermal cannabinoid treatment for patients suffering Fragile X syndrome, the most common form of inherited learning disability and attention deficit disorder. Interestingly, the company’s flagship product ZYN002 is a synthetic cannabidiol (CBD), which […]

by

While the legal landscape continues to evolve in the cannabis industry, making entry into the space a potentially risky proposition,  the passage of the Agriculture Improvement Act of 2018 (the “Farm Bill”) can be a real game changer in attracting mainstream companies to the industry. According to the Farm Bill, hemp is now exempt from […]

by

While the legal landscape continues to evolve in the cannabis industry, making entry into the space a potentially risky proposition,  the passage of the Agriculture Improvement Act of 2018 (the “Farm Bill”) can be a real game changer in attracting mainstream companies to the industry. According to the Farm Bill, hemp is now exempt from […]

by

While the legal landscape continues to evolve in the cannabis industry, making entry into the space a potentially risky proposition,  the passage of the Agriculture Improvement Act of 2018 (the “Farm Bill”) can be a real game changer in attracting mainstream companies to the industry. According to the Farm Bill, hemp is now exempt from […]

by

FinancialBuzz.com News Commentary NEW YORK, April 29, 2019 /PRNewswire/ — Dozens of countries across the world have moved to legalize cannabis in some form, even though the majority of these countries are only allowing cannabis for medical applications. The plant is comprised of two main components, tetrahydrocannabinol (THC) and cannabidiol (CBD). However, the two compounds […]

by

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) has earned a consensus recommendation of “Buy” from the six research firms that are covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price target among analysts that have issued ratings […]

by

Sankaty Advisors Llc decreased its stake in Skyline Champion Corporation (SKY) by 29.6% based on its latest 2018Q4 regulatory filing with the SEC. Sankaty Advisors Llc sold 2.01 million shares as the company’s stock declined 5.55% while stock markets rallied. The hedge fund held 4.79M shares of the homebuilding company at the end of 2018Q4, […]

by

Investment analysts at Roth Capital began coverage on shares of Zynerba Pharmaceuticals (NASDAQ:ZYNE) in a research note issued on Tuesday, BenzingaRatingsTable reports. The brokerage set a “buy” rating on the stock. ZYNE has been the subject of several other research reports. Zacks Investment Research raised shares of Zynerba Pharmaceuticals from a “hold” rating to a […]

by

By Palash Krishna Mehrotra Just about everybody smokes marijuana in India. Hush, not a word to anybody. We will all be arrested. It’s a democratic, egalitarian weed loved by copywriters, doctors, designers, salesmen, delivery boys, auto-rickshaw drivers, cycle-rickshaw pullers, NGO employees, journalists, chauffeurs, housewives, house husbands, army men, policemen, schoolteachers, college professors, train TTs, corporate […]

by